tbuckley/cabot-search huggingface dataset:
Abstract P6-09-41: Factors predicting treatment outcomes of angiosarcoma of breast: A 25 year single institution experience
Authors: N Ammannagari, K Attwood, R Cheney, JS Young, JM Kane, KE Salerno, M Opyrchal
Journal: Cancer Research (2017)

Abstract Background: Primary (PAS) and secondary angiosarcoma (SAS) of breast account for &amp;lt; 1% of all breast neoplasms. SAS develops following radiation therapy (RT) to the breast or chest wall for treatment of breast cancer. The rarity of this tumor type makes it challenging to determine prognostic factors and develop optimal treatment strategies. Historically, large NCI cancer centers have reported a median overall survival ranging from 28 – 100 months with recurrence rate of 55%. Methods: We reviewed demographic, tumor, and treatment characteristics of breast AS patients diagnosed and treated at our institution between 1990 and 2015. Overall (OS) and recurrence free (RFS) survival were compared using standard statistical methods at a significance level of 0.05. Results: Of 12155 breast cancers, 22 patients (0.008%) with AS (PAS in 34%, SAS in 66%) were identified. Median age of PAS patients was significantly lower than SAS – 45 vs 71 years (p &amp;lt; 0.001). Median tumor size was 6.9 cm (7.3 cm vs 6.9 cm, p = 0.93) with multifocal disease seen in 22.7%. Tumor was high grade in 14 (50% vs 83.3%, p = 0.34). Median time from RT to SAS diagnosis was 7.8 years. Treatment included: mastectomy in 17 (77.3%), wide excision in 4 (18.2%), adjuvant RT in 4 (18.2%), taxane based chemotherapy in 11 (50%) and chemo-RT in 1 (4.5%). No significant differences were noted in tumor (p = 0.9) or treatment characteristics (p = 0.4) between PAS and SAS. Recurrence rate (mainly distant) was 36% (8 pts). The 5-year OS and RFS rates were 51% (95% CI 27–72%) and 36% (95% CI 14–58%) with estimated medians of 64.2 and 55.5 months, respectively with no significant difference between the two groups. Black ethnicity (11.6 vs 64.2 months, p = 0.015), multifocal disease (15.5 vs 64.2 months, p = 0.004) and tumor size of &amp;gt; 6.9 cm (8.3 vs 64.2 months, p = 0.03) were associated with poorer outcomes. Tumor grade was not related to OS. Adjuvant treatment (RT p = 0.49, chemotherapy p = 0.36) conferred no RFS or OS benefit. Conclusions: Patients with PAS were younger than SAS. Black race, multifocal presentation and larger tumor size predict worse clinical outcomes. Our institutional experience confirms the poor prognosis of angiosarcoma, and highlights the need for further research. Citation Format: Ammannagari N, Attwood K, Cheney R, Young JS, Kane JM, Salerno KE, Opyrchal M. Factors predicting treatment outcomes of angiosarcoma of breast: A 25 year single institution experience [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-09-41.
The animal naming test: An easy tool for the assessment of hepatic encephalopathy
Authors: Francesca Campagna, Sara Montagnese, Lorenzo Ridola, Marco Senzolo, Sami Schiff, Michele De Rui, Chiara Pasquale, Silvia Nardelli, Ilaria Pentassuglio, Carlo Merkel, Paolo Angeli, Oliviero Riggio, Piero Amodio
Journal: Hepatology (2017)

Screening for hepatic encephalopathy (HE) that does not cause obvious disorientation or asterixis (minimal HE [MHE]/grade 1 HE) is important. We examined if the animal naming test (ANT1 ) (maximum number of animals listed in 1 minute) is useful in this context. In total, 208 healthy controls, 40 controls with inflammatory bowel disease, and 327 consecutive patients with cirrhosis underwent the ANT1 . Patients were tested for MHE by the psychometric HE score, and 146 were assessed by electroencephalography; 202 patients were followed up regarding the occurrence of overt HE and death. In the healthy controls, ANT1 was influenced by limited education (<8 years) and advanced age (>80 years, P < 0.001). Using an age and education adjusting procedure, the simplified ANT1 (S-ANT1 ) was obtained. An S-ANT1 of <10 animals was abnormal. Of the patients, 169 were considered unimpaired, 32 as having HE ≥grade 2, and 126 as having MHE/grade 1 HE. This group had lower S-ANT1 than unimpaired patients (12 ± 0.4 versus 16 ± 0.7, P < 0.001) and higher S-ANT1 than those with HE ≥grade 2 (4 ± 0.9). In grade 1 HE the S-ANT1 was lower than in MHE. Following receiver operating characteristic analysis (Youden's index), 15 animals produced the best discrimination between unimpaired and MHE/grade 1 HE patients. Thus, a three-level score (0 for S-ANT1 ≥15, 1 for 10 ≤ S-ANT1 < 15, 2 for S-ANT1 <10) was obtained. This score was correlated both to the psychometric HE score (P < 0.0001) and to electroencephalography (P = 0.007). By sample random split validation, both S-ANT1 and its three-level score showed prognostic value regarding the 1-year risk of overt HE and death. No inflammatory bowel disease control had S-ANT <15.The S-ANT1 is an easily obtainable measure useful for the assessment of HE. (Hepatology 2017;66:198-208).
Prevalence of Monoclonal Gammopathy in Individuals Undergoing Routine Health Checkup in Brazil
Authors: Jose M Kutner, Eliane A Rosseto, Juliana Todaro, Michelle R Santos, Nea M Kashiwagi, Viviane A Tabone, Ana T Schwery, Raquel D Conceicao, Cristovao L Mangueira, Nelson Hamerschlak
Journal: Blood (2015)
Vinblastine Based Short-Pulse B-Non-Hodgkin’s Lymphoma Type Chemotherapy (CT) with Maintenance Therapy Is Highly Efficacious Treatment for Anaplastic Large Cell Lymphoma (ALCL).
Authors: Shripad D. Banavali, Lovenish Goyal, Roshni V. Bhagwat, Prasad Narayan, Sushil Mandhaniya, Brijesh Arora, Amish Vora, Suresh K. Pai, Sumeet Gujral, Purna A. Kurkure, Melissa Adde, Ian Magrath, Purvish M. Parikh
Journal: Blood (2006)
Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I–II, open-label, clinical study
Authors: Olivier Detry, Morgan Vandermeulen, Marie-Hélène Delbouille, Joan Somja, Noella Bletard, Alexandra Briquet, Chantal Lechanteur, Olivier Giet, Etienne Baudoux, Muriel Hannon, Frederic Baron, Yves Beguin
Journal: Journal of Hepatology (2017)

<h3>Background & Aims</h3> Mesenchymal stromal cell (MSC) infusion could be a means to establish tolerance in solid organ recipients. The aim of this prospective, controlled, phase I study was to evaluate the feasibility, safety and tolerability of a single infusion of MSCs in liver transplant recipients. <h3>Methods</h3> Ten liver transplant recipients under standard immunosuppression received 1.5–3×10<sup>6</sup>/kg third-party unrelated MSCs on postoperative day 3±2, and were prospectively compared to a control group of ten liver transplant recipients. As primary endpoints, MSC infusion toxicity was evaluated, and infectious and cancerous complications were prospectively recorded until month 12 in both groups. As secondary endpoints, rejection rate, month-6 graft biopsies, and peripheral blood lymphocyte phenotyping were compared. Progressive immunosuppression weaning was attempted from month 6 to 12 in MSC recipients. <h3>Results</h3> No variation in vital parameters or cytokine release syndrome could be detected during and after MSC infusion. No patient developed impairment of organ functions (including liver graft function) following MSC infusion. No increased rate of opportunistic infection or <i>de novo</i> cancer was detected. As secondary endpoints, there was no difference in overall rates of rejection or graft survival. Month-6 biopsies did not demonstrate a difference between groups in the evaluation of rejection according to the Banff criteria, in the fibrosis score or in immunohistochemistry (including Tregs). No difference in peripheral blood lymphocyte typing could be detected. The immunosuppression weaning in MSC recipients was not successful. <h3>Conclusions</h3> No side effect of MSC infusion at day 3 after liver transplant could be detected, but this infusion did not promote tolerance. This study opens the way for further MSC or Treg-based trials in liver transplant recipients. <h3>Lay summary</h3> Therapy with mesenchymal stromal cells (MSCs) has been proposed as a means to improve results of solid organ transplantation. One of the potential MSC role could be to induce tolerance after liver transplantation, <i>i.e.</i> allowing the cessation of several medications with severe side effects. This study is the first-in-man use of MSC therapy in ten liver transplant recipients. This study did not show toxicity after a single MSC infusion but it was not sufficient to allow withdrawal of immunosuppression. Clinical trial registration number: Eudract: # 2011-001822-81, ClinicalTrials.gov: # NCT 01429038.
Induction of an Erythroid but Not Megakaryocytic Expression Signature in Myeloid Cells By in Vitro 5-Aza-2'-Deoxycytidine Treatment
Authors: Rainer Claus, Philipp Sander, Dietmar Pfeifer, Lioudmila Bogatyreva, Emmanuel Bissé, Michael Lübbert
Journal: Blood (2015)
Childhood Cancer Survivors' Knowledge About Their Past Diagnosis and Treatment
Authors: Nina S. Kadan-Lottick, Leslie L. Robison, James G. Gurney, Joseph P. Neglia, Robert Hayashi, Melissa Hudson, C. Mertens
Journal: JAMA (2017)

summary of all of the elements oftheircancerhistory.Noonecouldpro-vide an accurate detailed summary,ie, the detailed name of the cancer,whether doxorubicin or daunorubicinwas administered, and the site of anyradiation therapy. Participants in oursample are participants in the CCSSand, thus, likely represent a motivatedand knowledgeable group. Accord-ingly, rates of diagnosis knowledgeamong childhood cancer survivors, ingeneral, may well be lower.Contrary to our a priori hypotheses,our analyses suggest that no consistentfactors identify individuals with inad-equate knowledge of their cancer diag-nosis and therapy. Of note, no interac-tionwasfoundbetweenageatdiagnosisand era of diagnosis. Also, individualswho attended a long-term follow-upclinic or received a medical summary,interventionsreceivingattentionintheliterature, 10,11 didnotdisplaygreaterun-derstandingoftheirdiagnosisandtreat-ment. In fact many of the participantsdidnotknowwhethertheyeverhadre-ceived these interventions.We observed particularly disturb-ing knowledge deficits in anthracy-cline exposure and site of radiationtherapy,withlackofawarenessamongmore than half of those who had re-ceived such treatments. These thera-piesarepotentiallyassociatedwithcon-siderabletoxiceffectsthatwarrantclosemonitoring, as reported in a consen-sus statement from the CardiologyCommittee of the Children’s CancerStudy Group.
Remission Induction in a Phase I/II Study of an Anti-CD20-Interleukin-2 Immunocytokine DI-Leu16-IL2 in Patients with Relapsed B-Cell Lymphoma
Authors: Veronika Bachanova, Frederick Lansigan, Donald P. Quick, Daniel Vlock, Stephen Gillies, Ryotaro Nakamura
Journal: Blood (2015)
Apoptosis Might Contribute to the Thrombocytopenia in Heparin-Induced Thrombocytopenia
Authors: Tatiana A. Nevzorova, Elmira R. Mordakhanova, Anastasia A. Ponomareva, Izabella A. Andrianova, Rustem I. Litvinov, John W. Weisel, Lubica Rauova
Journal: Blood (2016)
Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)—Decog-trial.
Authors: Thomas K. Eigentler, Ralf Gutzmer, Axel Hauschild, Eckhart Kämpgen, Dirk Schadendorf, Dorothee Nashan, Erhard Hölzle, Uwe Trefzer, Jürgen C. Becker, Cord Sunderkötter, Ingrid Moll, Erika Richtig, Iris Pönitzsch, Hubert Pehamberger, Roland Kaufmann, Claudia Pfoehler, Thomas Vogt, Carola Berking, Michael Praxmarer, Claus Garbe
Journal: Journal of Clinical Oncology (2014)

9071 Background: Adjuvant treatment with IFN improved disease free survival (DFS) and showed a trend for improving overall survival (OS). PEG-IFN has a prolonged half life time and is just given once weekly. This trial was designed to examine if PEG-IFN is superior to IFN in regard to distant metastasis free survival (DMFS), DFS and OS. Methods: In this multicenter, open-label, prospective randomized phase III trial, patients (pts) with resected cutaneous melanoma stage IIA(T3a)-IIIB (AJCC 2002) were randomized to receive IFN (3 MU subcutaneously [sc] 3x/week; 24 months) or to PEG-IFN (180 mcg sc 1x/week; 24 months). Randomization was stratified for tumor stage, number of metastatic nodes, patient’s age and previous interferon treatment. Primary endpoint was DMFS, secondary endpoints were OS, DFS, quality of life and tolerability. Sample size (880 pts) was calculated on an expected difference of 55% vs 45% in the 5 years DMFS rate and assuming 80% power (2-sided, significance level 5%). Non-parametric survival models using log-rank tests and Cox regression models were performed on the ITT population. Results: Of 909 pts enrolled, 907 (451 PEG, 458 IFN) were eligible for evaluation after a median follow-up of 5.0 years. Neither DMFS (PEG-IFN 65.1% vs IFN 70.2%, p=0.18; HR, 1.16; 95% CI, 0.92-1.5) nor OS (74.2% vs 74.8%, p=0.13; HR, 1.05; 95% CI, 0.81-1.37) nor DFS (57.9% vs 60.8%, p=0.49; HR, 1.06; 95% CI, 0.86 to 1.31) showed significant differences. Subgroup analyses of PEG-IFN vs IFN in pts +/- ulcerated primaries and of different tumor stages did not find differences in DMFS, OS or DFS. 118 pts (26.1%) in the PEG-IFN and 61 pts (13.3%) in the IFN population did not receive the scheduled full dose and length of treatment due to adverse events (p<0.001). Leucopenia (CTC grade 2+) and elevation of liver enzymes (grade 2+) were more frequent in the PEG-IFN arm (56% vs 23.5% LCP; 19.1% vs 9.4 % AST; 33.0% vs 16.5% ALT). Conclusions: PEG-IFN did not improve the outcome parameters over conventional IFN. CTC grade 2+ toxicity was significantly more pronounced and a higher percentage of pts under PEG-IFN discontinued treatment prematurely. Clinical trial information: NCT00204529.
Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma
Authors: Chrissy H.Y. van Beurden-Tan, Margreet G. Franken, Hedwig M. Blommestein, Carin A. Uyl-de Groot, Pieter Sonneveld
Journal: Journal of Clinical Oncology (2017)

Purpose Since 2000, many new treatment options have become available for relapsed and/or refractory multiple myeloma (R/R MM) after a long period in which dexamethasone and melphalan had been the standard treatment. Direct comparisons of these novel treatments, however, are lacking. This makes it extremely difficult to evaluate the relative added value of each new treatment. Our aim was to synthesize all efficacy evidence, enabling a comparison of all current treatments for R/R MM. Methods We performed a systematic literature review to identify all publicly available phase III randomized controlled trial evidence. We searched Embase, MEDLINE, MEDLINE In-Process, Cochrane Central Register of Controlled Clinical Trials, and the Web site www.ClinicalTrials.gov . In addition, two trials presented at two international hematology congresses (ie, ASCO 2016 and European Hematology Association 2016) were added to include the most recent evidence. In total, 17 randomized controlled trials were identified, including 18 treatment options. The evidence was synthesized using a conventional network meta-analysis. To include all treatments within one network, two treatment options were combined: (1) bortezomib monotherapy and bortezomib plus dexamethasone, and (2) thalidomide monotherapy and thalidomide plus dexamethasone. Results The combination of daratumumab, lenalidomide, and dexamethasone was identified as the best treatment. It was most favorable in terms of (1) hazard ratio for progression-free survival (0.13; 95% credible interval, 0.09 to 0.19), and (2) probability of being best (99% of the simulations). This treatment combination reduced the risk of progression or death by 87% versus dexamethasone, 81% versus bortezomib plus dexamethasone, and 63% versus lenalidomide plus dexamethasone. Conclusion Our network meta-analysis provides a complete overview of the relative efficacy of all available treatments for R/R MM. Until additional data from randomized studies are available, on the basis of this analysis, the combination of daratumumab, lenalidomide, and dexamethasone seems to be the best treatment option.
Standards for Reporting Implementation Studies (StaRI) Statement
Authors: Hilary Pinnock, Melanie Barwick, Christopher R Carpenter, Sandra Eldridge, Gonzalo Grandes, Chris J Griffiths, Jo Rycroft-Malone, Paul Meissner, Elizabeth Murray, Anita Patel, Aziz Sheikh, Stephanie J C Taylor
Journal: BMJ (2017)

Implementation studies are often poorly reported and indexed, reducing their potential to inform initiatives to improve healthcare services. The Standards for Reporting Implementation Studies (StaRI) initiative aimed to develop guidelines for transparent and accurate reporting of implementation studies. Informed by the findings of a systematic review and a consensus-building e-Delphi exercise, an international working group of implementation science experts discussed and agreed the StaRI Checklist comprising 27 items. It prompts researchers to describe both the implementation strategy (techniques used to promote implementation of an underused evidence-based intervention) and the effectiveness of the intervention that was being implemented. An accompanying Explanation and Elaboration document (published in BMJ Open, doi:10.1136/bmjopen-2016-013318) details each of the items, explains the rationale, and provides examples of good reporting practice. Adoption of StaRI will improve the reporting of implementation studies, potentially facilitating translation of research into practice and improving the health of individuals and populations.
Global Risk Profile Verification in Patients with Venous Thromboembolism (GRIP VTE) in Five Gulf Countries.
Authors: Faisal Al Sayegh, Wael Almahmeed, Mahmoud Marashi, Ahmed Bahr, Hasan Al Mahdi, Sherif Bakir, Salah Al Humood, Maha Al Farhan
Journal: Blood (2004)
Relapsed and Refractory Primary Mediastinal Diffuse Large B-Cell Lymphoma: Outcome with ICE-Based Treatment.
Authors: Paul A. Hamlin, Mark Dickson, Tarun Kewalramani, Steven M. Horwitz, Carol S. Portlock, Joachim Yahalom, Andrew D. Zelenetz, Craig H. Moskowitz
Journal: Blood (2006)
Effect of endocrine therapy with tamoxifen on hormone receptor status in patients with breast cancer
Authors: S. Djahansouzi, V. Rostock, D. Niederacher, D. Rein, W. Rath, H. Bender
Journal: Journal of Clinical Oncology (2009)

e11598 Background: Endocrine therapy (ET) of patients with hormone receptor (HR)-positive breast cancer (BC) is thought to adversely affect the HR status of the tumor with time. In order to evaluate this, a study was undertaken comparing the HR status of patients with estrogen receptor (ER)-positive BC prior to adjuvant tamoxifen (Tam) therapy and after progression. Methods: A retrospective analysis of all BC patients presented to the unit between 1999 to 2004 with an initial stage I-III ER-positive BC, who received Tam between 6 and 60 month and went on to develop progressive disease in the form of local recurrence or distant metastasis. Progression was confirmed by tumor biopsy and analysis of the HR status. All patients were evaluated for ER and progesterone receptor (PR) status using immunohistochemistry as well as tumor grading prior to Tam therapy and after relapse. Results: 67 eligible patients with ER-positive BC were recorded. All patient and tumor characteristics, including age, tumor size, histology and adjuvant therapy were similar as published elsewhere. 82% were initially PR-positive. The mean duration of Tam administration of 20mg po was 40.7±19.9 month. The mean duration to progression was calculated at 54.9±34.6 month. After relapse, 70.1% of tumors retained a positive ER status and only 53% showed positive PR expression. Using the nonparametric McNemar's test, a highly significant reduction (p&lt; 0.001) of both HR was the result of Tam administration. Conclusions: our data suggests that progression under ET shows a trend towards loss of HR status (ER as well as PR). Therefore, this data is a useful tool for the clinician in evaluating the effectiveness of further ET in patients with progressive BC without having been able to confirm the present HR status through biopsy. Furthermore, as opposed to common belief, the reduction in positive ER tumors showed no correlation with tumor grading. No significant financial relationships to disclose.
Prognostic impact of circulating HER2 extracellular domain (ECD) in women with metastatic breast cancer.
Authors: Yabing Zheng, Xiying Shao, Xiaojia Wang, Lei Shi, Yuan Huang
Journal: Journal of Clinical Oncology (2015)

e22038 Background: Overexpression of HER2, usually as a result of HER2 gene amplification, occurs in approximately 25% of breast cancers and is significantly associated with aggressive disease and markedly decreased survival. HER2 is composed of a cytoplasmic domain with tyrosine kinase activity, a transmembrane domain and an extracellular domain (ECD). The HER2 ECD may be cleaved and shed from the surface of breast cancer cells and can be detected by enzyme-linked immunosorbent assay (ELISA). Methods: This prospective trial included 113 patients with stage I–III breast cancer and 207 metastatic breast cancer patients from March 2009 to July 2011. Serum HER2 ECD levels were measured by enzyme-linked immunosorbent assays. Results: High serum HER2 ECD levels ( ≥ 15 ng/ml) were reported in 65 metastatic breast cancer (31.4%) and 1 early breast cancer patient (0.9%). High HER2 ECD levels were significantly associated with tissue HER2 positive (P= 0.017), abnormal CEA levels (P= 0.000), elevated CA125 levels (P= 0.000), high CA153 levels (P= 0.000), increased concentrations of LDH (P= 0.000), abnormal AKP levels (P= 0.002), liver involvement (P= 0.005), brain metastasis (P= 0.003) and visceral involved (P= 0.002) in metastatic breast cancer. While there was no significant correlation between HER2 ECD and age, BMI, tumor size, lymph node involvement and hormone receptors (P> 0.05). Likewise, HER2 ECD levels were not related to tissue HER2 status, clinicopathological parameters and tumor markers in patients with early breast cancer (P> 0.05). Conclusions: Monitoring the circulating levels of the HER2 ECD in patients with metastatic breast cancer provides a real-time assessment of the HER2 status and indicates poor prognosis, and may provide important information for routine management in metastatic breast cancer.
Assessment of the Immune Reconstitution by Cylex Immuknow™ Assay in Patients after Allogeneic Stem Cell Transplantation.
Authors: Benjamin Gesundheit, Yehudit Azar, Rachel Bringer, Schivti Steinberg-Prop, Moshe Israeli, Michael Y. Shapira, Igor Resnick, Simcha Samuel, Shimon Slavin, Reuven Or
Journal: Blood (2006)
Treatment of Large Established Murine Melanoma with Th17 Polarized CD4+ T Helper Cells Genetically Engineered to Express MHC Class IIRestricted T Cell Receptor
Authors: Pawel Muranski, Christian S. Hinrichs, Luis Sanchez-Perez, Andrea Boni, Sid Kerkar, Luca Gattinoni, Zhia Yu, Nicholas P. Restifo
Journal: Blood (2008)